Galectin-3 in Heart Failure An Update of the Last 3 Years

被引:88
|
作者
Gehlken, Carolin [1 ]
Suthahar, Navin [1 ]
Meijers, Wouter C. [1 ]
de Boer, Rudolf A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, POB 30-001, NL-9700 RB Groningen, Netherlands
关键词
Galectin-3; Heart failure; Fibrosis; inhibitor; Biomarker; Prognosis; MODIFIED CITRUS PECTIN; PROGNOSTIC VALUE; CARDIOVASCULAR-DISEASE; MYOCARDIAL FIBROSIS; PREDICTIVE-VALUE; PERFORMANCE-CHARACTERISTICS; RISK STRATIFICATION; SERIAL MEASUREMENTS; CARDIAC BIOMARKERS; EUROPEAN-SOCIETY;
D O I
10.1016/j.hfc.2017.08.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications. In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3-centered diseases.
引用
收藏
页码:75 / +
页数:19
相关论文
共 50 条
  • [21] Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites
    McEvoy, John W.
    Chen, Yuan
    Halushka, Marc K.
    Christenson, Eric
    Ballantyne, Christie M.
    Blumenthal, Roger S.
    Christenson, Robert H.
    Selvin, Elizabeth
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (05):
  • [22] Galectin-3 testing with the Vidas® assay in patients with heart failure
    Gruson, Damien
    Mancini, Mehdi
    Ahn, Sylvie
    Rousseau, Michel
    ACTA CARDIOLOGICA, 2014, 69 (01) : 77 - 77
  • [23] Comprehensive Review of the Prognostic Value of Galectin-3 in Heart Failure
    Coburn, Elliot
    Frishman, William
    CARDIOLOGY IN REVIEW, 2014, 22 (04) : 171 - 175
  • [24] Cystatin C and galectin-3 as therapeutic targets in heart failure
    Zivlas, Christos
    Triposkiadis, Filippos
    Psarras, Stelios
    Giamouzis, Gregory
    Skoularigis, Ioannis
    Chryssanthopoulos, Stavros
    Kapelouzou, Alkistis
    Ramcharitar, Steve
    Barnes, Edward
    Papasteriadis, Evangelos
    Cokkinos, Dennis
    THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2018, 12 (08) : 233 - 235
  • [25] Soluble ST2 and Galectin-3 in Heart Failure
    Shah, Ravi V.
    Januzzi, James L., Jr.
    CLINICS IN LABORATORY MEDICINE, 2014, 34 (01) : 87 - +
  • [26] Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study
    Florido, Roberta
    Kwak, Lucia
    Echouffo-Tcheugui, Justin B.
    Zhang, Sui
    Michos, Erin D.
    Nambi, Vijay
    Goldberg, Ronald B.
    Hoogeveen, Ron C.
    Lazo, Mariana
    Gerstenblith, Gary
    Post, Wendy S.
    Blumenthal, Roger S.
    Coresh, Josef
    Folsom, Aaron R.
    Selvin, Elizabeth
    Ballantyne, Christie
    Ndumele, Chiadi E.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (09):
  • [27] Galectin-3: a novel mediator of heart failure development and progression
    de Boer, Rudolf A.
    Voors, Adriaan A.
    Muntendam, Pieter
    van Gilst, Wiek H.
    van Veldhuisen, Dirk J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (09) : 811 - 817
  • [28] Galectin-3: a new biomarker for heart failure progression and prognosis
    de Boer, Rudolf A.
    van der Velde, A. Rogier
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2013, 37 (05): : 251 - 260
  • [29] Galectin-3 in heart failure pathology -"another brick in the wall"?
    Lala, Radu I.
    Puschita, Maria
    Darabantiu, Dan
    Pilat, Luminita
    ACTA CARDIOLOGICA, 2015, 70 (03) : 323 - 331
  • [30] Galectin-3 levels in patients hospitalized for decompensated heart failure
    Rossel, Victor
    Diaz-Toro, Felipe
    Verdejo, Hugo
    Concepcion, Roberto
    Sepulveda, Luis
    Castro, Pablo
    Luis Vukasovic, Jose
    Bernales, Angie
    REVISTA MEDICA DE CHILE, 2017, 145 (06) : 734 - 740